Literature DB >> 29748577

Reversible glycosidic switch for secure delivery of molecular nanocargos.

Pierre-Alain Burnouf1,2,3, Yu-Lin Leu4, Yu-Cheng Su2, Kenneth Wu2, Wei-Chi Lin4, Steve R Roffler5,6.   

Abstract

Therapeutic drugs can leak from nanocarriers before reaching their cellular targets. Here we describe the concept of a chemical switch which responds to environmental conditions to alternate between a lipid-soluble state for efficient cargo loading and a water-soluble state for stable retention of cargos inside liposomes. A cue-responsive trigger allows release of the molecular cargo at specific cellular sites. We demonstrate the utility of a specific glycosidic switch for encapsulation of potent anticancer drugs and fluorescent compounds. Stable retention of drugs in liposomes allowed generation of high tumor/blood ratios of parental drug in tumors after enzymatic hydrolysis of the glycosidic switch in the lysosomes of cancer cells. Glycosidic switch liposomes could cure mice bearing human breast cancer tumors without significant weight loss. The chemical switch represents a general method to load and retain cargos inside liposomes, thereby offering new perspectives in engineering safe and effective liposomes for therapy and imaging.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29748577      PMCID: PMC5945669          DOI: 10.1038/s41467-018-04225-5

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


  53 in total

Review 1.  Transfer of lipophilic drugs between liposomal membranes and biological interfaces: consequences for drug delivery.

Authors:  Alfred Fahr; Peter van Hoogevest; Sylvio May; Nill Bergstrand; Mathew L S Leigh
Journal:  Eur J Pharm Sci       Date:  2005-11       Impact factor: 4.384

Review 2.  Topoisomerase I inhibitors: camptothecins and beyond.

Authors:  Yves Pommier
Journal:  Nat Rev Cancer       Date:  2006-10       Impact factor: 60.716

3.  Design and synthesis of water-soluble glucuronide derivatives of camptothecin for cancer prodrug monotherapy and antibody-directed enzyme prodrug therapy (ADEPT).

Authors:  Y L Leu; S R Roffler; J W Chern
Journal:  J Med Chem       Date:  1999-09-09       Impact factor: 7.446

4.  Higher liposomal membrane fluidity enhances the in vitro antitumor activity of folate-targeted liposomal mitoxantrone.

Authors:  Kumi Kawano; Eri Onose; Yoshiyuki Hattori; Yoshie Maitani
Journal:  Mol Pharm       Date:  2009 Jan-Feb       Impact factor: 4.939

5.  Development of potent monoclonal antibody auristatin conjugates for cancer therapy.

Authors:  Svetlana O Doronina; Brian E Toki; Michael Y Torgov; Brian A Mendelsohn; Charles G Cerveny; Dana F Chace; Ron L DeBlanc; R Patrick Gearing; Tim D Bovee; Clay B Siegall; Joseph A Francisco; Alan F Wahl; Damon L Meyer; Peter D Senter
Journal:  Nat Biotechnol       Date:  2003-06-01       Impact factor: 54.908

6.  Stability of the new prodrug 9-aminocamptothecin glucuronide (9ACG) in the presence of human serum albumin.

Authors:  Zeljko M Prijovich; Yu-Lin Leu; Steve R Roffler
Journal:  Biochem Pharmacol       Date:  2003-10-01       Impact factor: 5.858

7.  Potential of poly(amidoamine) dendrimers as drug carriers of camptothecin based on encapsulation studies.

Authors:  Yiyun Cheng; Mingzhong Li; Tongwen Xu
Journal:  Eur J Med Chem       Date:  2007-12-07       Impact factor: 6.514

8.  A minimal toxicity approach to cancer therapy: possible role of beta-glucuronidase.

Authors:  D M Rubin; E J Rubin
Journal:  Med Hypotheses       Date:  1980-01       Impact factor: 1.538

9.  Lysosome-targeted octadecyl-rhodamine B-liposomes enhance lysosomal accumulation of glucocerebrosidase in Gaucher's cells in vitro.

Authors:  Ritesh Thekkedath; Alexander Koshkaryev; Vladimir P Torchilin
Journal:  Nanomedicine (Lond)       Date:  2012-12-02       Impact factor: 5.307

10.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs.

Authors:  Y Matsumura; H Maeda
Journal:  Cancer Res       Date:  1986-12       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.